Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 19/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728234 | 0.93 | HMGCR (0.79) | HMGCR | |
| SCHEMBL5732783 | 0.92 | HMGCR (0.85) | HMGCR | |
| SCHEMBL5733041 | 0.91 | HMGCR (0.84) | HMGCR | |
| SCHEMBL5733046 | 0.91 | HMGCR (0.94) | HMGCR | |
| SCHEMBL5732039 | 0.90 | HMGCR (0.90) | HMGCR | |
| SCHEMBL5732179 | 0.90 | HMGCR (0.74) | HMGCR | |
| SCHEMBL6504334 | 0.89 | HMGCR (0.89) | HMGCR | |
| SCHEMBL5731182 | 0.89 | HMGCR (0.84) | HMGCR | |
| SCHEMBL6504337 | 0.89 | HMGCR (1.00) | HMGCR | |
| SCHEMBL5731109 | 0.85 | HMGCR (0.85) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691803-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | Warner-Lambert Company LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005056004-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | HMGCR 1956/4885 |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.